系统性红斑狼疮血清可溶性DcR3水平表达及与临床用药关系探讨

Expression of serum soluble decoy receptor 3(DcR3) in systemic lupus erythematosus and relation with clinical medicine treatment

目的:探讨系统性红斑狼疮血清可溶性DcR3(Decoy receptor3)水平表达及与治疗药物的关系。方法:收集SLE患者51例,健康对照组19例,用酶联免疫吸附试验(ELISA)检测血清可溶性DcR3浓度,采用SLE疾病活动指数(SLEDAI)评判SLE疾病活动性,分析SLE治疗方案中主要用药(泼尼松、环磷酰胺、硫唑嘌呤、羟氯喹、白芍总苷)与血清可溶性DcR3浓度及SLEDAI的关系。结果:SLE患者血清可溶性DcR3浓度显著高于正常对照组(t=2.42,P<0.05),而且与SLEDAI积分呈正相关(r=0.373,P<0.01),SLE治疗方案中使用泼尼松组DcR3浓度比未使用组显著升高(P<0.05),而使用羟氯喹组却显著降低,此外使用泼尼松、环磷酰胺组比不使用组有较高SLEDAI积分。结论:血清可溶性DcR3在SLE中高表达,与SLEDAI呈正相关,治疗药物对血清DCR3浓度影响不明显,可以作为SLE诊断和评判疾病活动度的指标。

Objective：To explore the expression of serum soluble decoy receptor 3（DcR3） in systemic lupus erythematosus（SLE） and relation with clinical medicine treatment.Methods： 51 patients with SLE and 19 healthy controls were collected.The levels of serum soluble DcR3 were detected by enzyme linked immunosorbent assay（ELISA）.SLE disease activity index（SLEDAI） were used to assess the disease activity in SLE,and the relevance between the main medcine（prednisone,cyclophosphamide,azathioprine,hydroxychloroquine） in SLE treatment with serum soluble DcR3 and SLEDAI were analyzed.Results： The concentrations of serum soluble DcR3 were markedly higher in SLE group than those in the control group（t=2.42,P0.05）,and it was positively correlated with SLEDAI（r=0.373,P0.01）.In particular,serum soluble DcR3 levels of SLE patients treated with a regimen containing prednisone were significantly higher than those without using prednisone（P 0.05）,while serum soluble DcR3 level was much lower in group treated with a regimen containing hydroxychloroquine.Furthermore,a regimen containing prednisone or cyclophosphamide showed a higher SLEDAI score than those not containing.Conclusion： Serum soluble DcR3 expression in SLE increased and positively correlated with SLEDAI.The influence of medication on serum soluble DCR3 is not obvious and it can serve as an indicator for SLE diagnosis and evaluation of SLE disease activity.